Comparing dual-energy CT and MRI for staging oral and oropharyngeal squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares 40 keV dual-energy CT (with the BOLT maneuver) to standard contrast-enhanced cervicofacial MRI for determining TNM stage in adults with oral or oropharyngeal squamous cell carcinoma. Eligible participants have biopsy-proven disease and undergo both imaging exams as part of their pre-therapeutic workup. Imaging results will be compared to determine concordance and to test non-inferiority of DECT relative to MRI for tumor and nodal staging. If DECT proves non-inferior, it could shorten the pre-treatment imaging pathway and reduce reliance on MRI resources.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient (≥18 years)
* presenting with oral or oropharyngeal squamous cell carcinoma proven by histopathological analysis of a biopsy
* having undergone a clinical examination with nasofibroscopy by an ENT surgeon specializing in cancer surgery
* a contrast-enhanced cervicofacial MRI
* and a contrast-enhanced cervicofacial DECT with BOLT maneuver.

Exclusion Criteria:

* A lesion other than oral or oropharyngeal squamous cell carcinoma
* A labial location
* A contraindication to performing one or both of the imaging examinations.

Where it's running

• Service d'ORL et de Chirurgie Cervico-faciale - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Philippe Schultz, MD, PhD
• Email: philippe.schultz@chru-strasbourg.fr
• Phone: 33 3 88 12 76 36

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Testing a new saliva test for oral and throat cancer

  This study is testing a new saliva test to see if it can help find oral and throat cancers in people who might have them.

  Recruiting at 2 sites Viome · St Louis, Missouri and 1 other locations · NCT06174428

• Combining sintilimab with reduced chemotherapy for oral cavity cancer treatment

  This study is testing if combining a new immune therapy called sintilimab with fewer chemotherapy sessions can help people with certain types of mouth cancer before they have surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05098119

• Salivary IL-8 and Serum IL-6 as Biomarkers to Distinguish Oral Premalignant Disorders in Smokers and Never-Smokers

  This study tests whether salivary IL-8 and blood IL-6 can help tell apart adults with oral premalignant conditions from those with healthy mouths, and whether smoking influences these markers.

  Recruiting British University In Egypt · Cairo · NCT07915570

• Patient-specific 3D-printed titanium implants for facial reconstruction

  This study tests whether custom-made 3D-printed titanium facial implants can improve reconstruction and appearance for adults with facial bone defects or asymmetry.

  Recruiting Latakia University · Latakia · NCT07654647

• Lowering nodal and primary tumor radiation dose in HPV-positive oropharyngeal cancer

  This phase II study tests whether reducing radiation doses to regions without visible cancer, while keeping the main tumor dose the same, can treat HPV-positive OPSCC with fewer side effects.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07497607

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.